Fortis Healthcare
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin r...
Fortis Healthcare vs Akums Drugs & Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Akums Drugs &
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations.
Result Snapshot
Revenue₹2,265 Cr₹1,160 Cr
PAT₹197 Cr₹68 Cr
EBITDA Margin22.3%12.7%
Sentimentbullishbullish
Key Quotes
Our business performance in Q3 has been good considering the seasonal impact of festivals in some of our key geographies.
Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.